Abstract:Abstract Background: Due to the rarity, the type 3 of maturity-onset diabetes of the young (MODY3) has not been explored comprehensively. The study aimed to describe and analyze the molecular and clinical characteristics of MODY3, which could help physicians understand the subtype of diabetes and increase the diagnosis rates in the future.Methods: Ten unrelated patients with suspected maturity-onset diabetes of the young (MODY) were included in the study based on information on family history and onset age. Sanger sequencing was used to identify cases with mutations in the hepatic nuclear factor 1A gene (HNF-1A). Results: Five patients were identified with MODY3, three cases (60%) with p.I27L mutation, one case (20%) with p.S487N mutation, and one case (20%) with p.G574S mutation. The average onset age was (23.00±3.00) years and the average age of diagnosis was (28.67±9.29) years. Most patients had typical clinical symptoms (polydipsia, polyuria, polyphagia, and weight loss). The main complications included diabetic ketoacidosis (DKA, 3/5,60%), diabetic macroangiopathy (2/5,40%), diabetic peripheral neuropathy (DPN,3/5,60%), diabetic nephropathy (DN,1/5,20%) and diabetic retinopathy (DR,1/5,20%). Four patients (80%) had fatty liver. The average body mass index (BMI) (26.39±4.67) kg/㎡, triglyceride (TG 2.95±1.43 mmol/L) and low-density lipoprotein (LDL-C 3.37±0.65 mmol/L) were beyond normal value. The glycosylated hemoglobin A1c (HbA1c 12.45±4.60 %), fasting plasma glucose (FPG 10.10±3.57 mmol/L) and postprandial plasma glucose (PPG 21.88±2.53 mmol/L) also increased dramatically. In addition, islet function examination revealed impaired secretion and slightly poor reserve function, which was similar to the changes inT2DM. All five patients used insulin, three (60%) also using antidiabetic drugs which did not include sulfonylureas.Conclusions: In brief, five patients were identified with MODY3. The mutation site could influence the onset age, the islet function and the incidence of complications. The age at diagnosis was 4.2 years later than the onset age. The control of diabetes was poor due to the inappropriate treatment. It is vital to make an early diagnosis and provide appropriate treatment for MODY3 patients.

Lysine 117 residue is essential for the function of the hepatocyte nuclear factor 1α

Mutation P291fsinsC in the Transcription Factor Hepatocyte Nuclear Factor-1Alpha is Dominant Negative

Novel Loss-of-Function Variant in HNF1a Induces beta-Cell Dysfunction through Endoplasmic Reticulum Stress

A Novel KLF11 Variant in a Family with Maturity-Onset Diabetes of the Young

Novel Loss-of-Function Variant in HNF1a Induces β-Cell Dysfunction through Endoplasmic Reticulum Stress

HNF4A and HNF1A exhibit tissue specific target gene regulation in pancreatic beta cells and hepatocytes

1596-P: Homozygous Mutations in MFN2 Aggravated Fat Deposition in Mouse Hepatocytes

A case report with functional characterization of a HNF1B mutation (p.Leu168Pro) causing MODY5

Studies of Genetic Variability of the Hepatocyte Nuclear Factor-1Α Gene in an Indian Maturity-Onset Diabetes of the Young Family.

A Novel HIF2A Mutation Causes Dyslipidemia and Promotes Hepatic Lipid Accumulation

Beta-Cell-Targeted Expression of A Dominant-Negative Hepatocyte Nuclear Factor-1 Alpha Induces A Maturity-Onset Diabetes of the Young (Mody)3-Like Phenotype in Transgenic Mice

KDM2A Deficiency in the Liver Promotes Abnormal Liver Function and Potential Liver Damage

Mouse KLF11 Regulates Hepatic Lipid Metabolism

Activation of the Insulin Gene Promoter through a Direct Effect of Hepatocyte Nuclear Factor 4α

Functional characterization of HNF4A gene variants identify promoter and cell line specific transactivation effects

Identification and Clinical Characteristics Analysis of HNF-1A Mutations p.I27L, p.S487N and p.G574S in Chinese Patients with MODY3

Novel Mechanisms of Regulation of the Expression and Transcriptional Activity of Hepatocyte Nuclear Factor 4Α

1H, 13C and 15N backbone resonance assignments of hepatocyte nuclear factor-1-beta (HNF1β) POUS and POUHD

The MODY1 Gene for Hepatocyte Nuclear Factor 4α and a Feedback Loop Control COUP-TFII Expression in Pancreatic Beta Cells

Mutant HNF-1alpha and mutant HNF-1beta identified in MODY3 and MODY5 downregulate DPP-IV gene expression in Caco-2 cells.

The MODY-associated L114P mutation increases islet glucagon secretion and limits insulin secretion resulting in transient neonatal diabetes and glucose dyshomeostasis in adults